Carisma Therapeutics, Inc.
CARM
$0.4411
-$0.0612-12.18%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 32.45% | 31.59% | 41.13% | 57.95% | 22.99% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 32.45% | 31.59% | 41.13% | 57.95% | 22.99% |
| Cost of Revenue | -31.46% | -19.50% | -12.75% | 4.27% | 16.21% |
| Gross Profit | 47.55% | 32.37% | 25.99% | 8.37% | -14.62% |
| SG&A Expenses | -26.76% | -31.79% | 1.55% | 22.76% | 51.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -30.27% | -23.00% | -9.30% | 8.48% | 23.52% |
| Operating Income | 41.36% | 32.18% | 18.17% | 0.05% | -23.62% |
| Income Before Tax | 37.58% | 30.39% | 22.39% | 8.43% | -9.24% |
| Income Tax Expenses | -- | -- | -200.00% | -200.00% | -200.00% |
| Earnings from Continuing Operations | 37.49% | 30.39% | 22.82% | 8.90% | -8.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 37.49% | 30.39% | 22.82% | 8.90% | -8.93% |
| EBIT | 41.36% | 32.18% | 18.17% | 0.05% | -23.62% |
| EBITDA | 41.46% | 33.84% | 19.57% | 0.75% | -22.29% |
| EPS Basic | 39.31% | 57.94% | 85.26% | 90.31% | 92.01% |
| Normalized Basic EPS | 41.78% | 59.25% | 85.20% | 90.28% | 91.99% |
| EPS Diluted | 39.31% | 57.94% | 85.26% | 90.31% | 92.01% |
| Normalized Diluted EPS | 41.78% | 59.25% | 85.20% | 90.28% | 91.99% |
| Average Basic Shares Outstanding | 2.95% | 24.01% | 72.16% | 184.10% | 741.59% |
| Average Diluted Shares Outstanding | 2.95% | 24.01% | 72.16% | 184.10% | 741.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |